Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, Lao-Sirieix S, Parashar D, Ahmad A, Daniel F, Hill M, Wilson G, Blesing C, Moody AM, McAdam K, Osborne M.

Br J Cancer. 2012 Aug 7;107(4):585-7. doi: 10.1038/bjc.2012.318. Epub 2012 Jul 19.

2.

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT.

JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.

PMID:
28715540
3.

Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.

Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, Chen G.

Ann Oncol. 2012 May;23(5):1348-53. doi: 10.1093/annonc/mdr400. Epub 2011 Sep 22.

PMID:
21940785
4.

Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.

Braik T, Yim B, Evans AT, Kassem M, Mullane M, Lad T, Hussein L, Cleveland B, McDunn S.

J Community Support Oncol. 2014 Feb;12(2):65-70.

PMID:
24971407
5.
6.

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.

Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL; North Central Cancer Treatment Group Study N05C5.

J Clin Oncol. 2010 Dec 10;28(35):5182-7. doi: 10.1200/JCO.2010.31.1431. Epub 2010 Nov 8.

7.

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.

Martín M, Martínez N, Ramos M, Calvo L, Lluch A, Zamora P, Muñoz M, Carrasco E, Caballero R, García-Sáenz JÁ, Guerra E, Caronia D, Casado A, Ruíz-Borrego M, Hernando B, Chacón JI, De la Torre-Montero JC, Jimeno MÁ, Heras L, Alonso R, De la Haba J, Pita G, Constenla M, González-Neira A.

Oncologist. 2015 Feb;20(2):111-2. doi: 10.1634/theoncologist.2014-0379. Epub 2015 Jan 19.

8.

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.

Wheeler HE, González-Neira A, Pita G, de la Torre-Montero JC, Alonso R, Lopez-Fernandez LA, Alba E, Martín M, Dolan ME.

Pharmacogenet Genomics. 2014 May;24(5):231-7. doi: 10.1097/FPC.0000000000000037.

9.

Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.

Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S.

Chem Res Toxicol. 2016 Oct 17;29(10):1591-1601. Epub 2016 Sep 28. Review.

PMID:
27631426
10.

Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.

Zhao C, Chen J, Yu B, Wu X, Dai C, Zhou C, Chen X.

J Tradit Chin Med. 2014 Feb;34(1):10-4.

11.

Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.

Chen M, Zhang L, Wang Q, Shen J.

PLoS One. 2013 Aug 20;8(8):e72245. doi: 10.1371/journal.pone.0072245. eCollection 2013. Review.

12.

Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study.

Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JW.

Drugs R D. 2017 Mar;17(1):117-124. doi: 10.1007/s40268-016-0154-8.

13.

Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

Elyasi S, Shojaee FSR, Allahyari A, Karimi G.

Phytother Res. 2017 Sep;31(9):1323-1329. doi: 10.1002/ptr.5857. Epub 2017 Jun 21.

PMID:
28635153
14.

Chemotherapy and fingerprint loss: beyond cosmetic.

Al-Ahwal MS.

Oncologist. 2012;17(2):291-3. doi: 10.1634/theoncologist.2011-0243. Epub 2012 Feb 1.

15.

Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.

Naito M, Yamamoto T, Hara S, Shimamoto C, Miwa Y.

Chemotherapy. 2017;62(1):23-29. Epub 2016 May 28.

PMID:
27229894
16.

Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.

Macedo LT, Lima JP, dos Santos LV, Sasse AD.

Support Care Cancer. 2014 Jun;22(6):1585-93. doi: 10.1007/s00520-014-2129-z. Epub 2014 Jan 26. Review.

PMID:
24463616
17.

Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.

Scontre VA, Martins JC, de Melo Sette CV, Mutti H, Cubero D, Fonseca F, Del Giglio A.

J Diet Suppl. 2017 Nov 2:1-7. doi: 10.1080/19390211.2017.1366387. [Epub ahead of print]

PMID:
29095653
18.

The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.

Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, Li G, Zhu H, Yang B, Luo P, He Q.

Environ Toxicol Pharmacol. 2017 Jan;49:81-88. doi: 10.1016/j.etap.2016.12.001. Epub 2016 Dec 5.

PMID:
27951409
19.

Capecitabine and the Risk of Fingerprint Loss.

van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R.

JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. No abstract available.

PMID:
27560202
20.

Capecitabine induced Hand-Foot Syndrome: Report of two cases.

Sanghi S, Grewal RS, Vasudevan B, Nagure A.

Med J Armed Forces India. 2013 Jan;69(1):65-7. doi: 10.1016/j.mjafi.2012.01.009. Epub 2012 Aug 14. No abstract available.

Supplemental Content

Support Center